The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation
Authors:
- 1 October 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 27 (5) , 666-676
Abstract
Everolimus is a novel proliferation signal inhibitor used in immunosuppressive therapies for the prevention of acute and chronic rejection. A role for everolimus drug monitoring has been suggested because of the potential for improving efficacy and reducing adverse effects. Everolimus has proven efficacy for prevention of rejection in adult de novo renal and cardiac transplant recipients. Similar effects have been shown in pediatric renal transplant patients. Several analytic methods are available to quantify everolimus concentrations. A good relationship exists between everolimus concentration and pharmacological response. Mere clinical monitoring of efficacy is insufficient because clinical presentations of graft rejection vary for each patient and are nonspecific. Thus, the authors have used a previously published 9-step decision-making algorithm to evaluate the utility of therapeutic drug monitoring for everolimus. The recommended therapeutic range for everolimus is a trough concentration of 3 to 8 ng/mL, as concentrations over 3 ng/mL have been associated with a decreased incidence of rejection, and concentrations >8 ng/mL with increased toxicity. Everolimus exhibits interindividual pharmacokinetic variability. African American patients have higher apparent clearance, whereas patients with hepatic dysfunction or those on concomitant medications with potent cytochrome P450 (CYP) 3A4 inhibitor or inducer properties have lower or higher apparent clearance, respectively. Solid organ transplant recipients will likely be maintained on immunosuppressant therapy for the life of the graft and/or recipient and thus are likely to benefit from clinical pharmacokinetic monitoring. Based on the available evidence, therapeutic drug monitoring for everolimus may provide additional information on efficacy and safety than sound clinical judgment alone. Patients on everolimus who have problems with absorption, who take concurrent cytochrome P450 inhibitors or inducers, or are noncompliant will attain the greatest benefit from drug monitoring.Keywords
This publication has 37 references indexed in Scilit:
- Cross-reactivity Of The Major Everolimus Hydroxy Metabolites With The Innofluor?? Certican?? Immunoassay For Clinical Tdm Of EverolimusTherapeutic Drug Monitoring, 2005
- Comparison of the Seradyn Innofluor?? Certican?? Assay on TDXFLX?? System With LC/MS-MSTherapeutic Drug Monitoring, 2005
- Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)The American Journal of Cardiology, 2005
- Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant RecipientsTransplantation, 2004
- Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipientsTransplant International, 2004
- Clinical Pharmacokinetics of EverolimusClinical Pharmacokinetics, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- Everolimus in pediatric de nova renal transplant patients1Transplantation, 2003
- Mycophenolate MofetilPharmacoEconomics, 2002
- Clinical Pharmacokinetics in the 21st CenturyClinical Pharmacokinetics, 1998